| Sandoz Pharmaceuticals AG - Rivastigmin Patch Sandoz 15, Transdermales Pflaster |
| 63164 | | 03 | | Rivastigmin Patch Sandoz 15 | | Transdermales Pflaster | | N06DA03 | | Rivastigmine | | 13.03.2014 | | |
|
| Composition |
| rivastigminum 27 mg, butylis methacrylatis et methylis methacrylatis polymerisatum, acrylic adhesive, int-rac-alpha-tocopherolum, silicone adhesive, dimeticonum, Trägermaterial: poly(ethylenis terephthalas), Drucktinte (Beige): ad praeparationem pro 15 cm², cum liberatione 13.3 mg/24h. |
| Packungsbestandteile |
| Transdermal patch | | | | | Active Agent | Dose |
|---|
| Rivastigmine | 27 mg |
| | BAG: Active Agent | Dose |
|---|
| Rivastigmine | 27 mg |
| | | | Inactive agents | Dose | additional_information |
|---|
| Acrylic Adhesive | | | | Butylis Methacrylatis | | | | Cum Liberatione | 13.3mg / 24h | | | Dimeticone | | | | Drucktinte (Beige): ad Praeparationem | 15 cm | | | Int-Rac-Alpha-Tocopherolum | | | | Methylis Methacrylatis Polymerisatum | | | | Poly(Ethylenis Terephthalas) | | Trägermaterial | | Silicone Adhesive | | |
| |
|
|
